Adjuvant diagnosis of tuberculosis in hemodialysis patients using fourth generation interferon γ releasing assay.
dialysis
interferon γ releasing assay
latent tuberculosis infection
tuberculosis
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
15
09
2022
received:
08
07
2022
accepted:
04
10
2022
medline:
28
4
2023
pubmed:
8
10
2022
entrez:
7
10
2022
Statut:
ppublish
Résumé
Dialysis patients have a 10-25 times higher risk of reactivation of tuberculosis (TB). In this study, we investigated the diagnostic ability of QuantiFERON (QFT)-plus for TB in hemodialysis patients. QFT-plus, an interferon gamma release assay, is characterized by its use of CD4 and CD8 T cell signals. Hemodialysis patients aged 20 years or older who underwent QFT-plus measurement in our hospital were included, inclusion criteria being fever above 37°C, high inflammatory response, and infiltrative pulmonary shadows. Forty-six patients were enrolled. Of these, 15% were QFT positive, 4% were diagnosed with active TB, 76% were QFT negative, 8% had inconclusive results. Sensitivity, specificity, positive predictive value, and negative predictive value were 100%, 87.5%, 28%, and 100%, respectively. QFT-plus may be useful for the diagnosis of active TB in dialysis patients. Further studies in cohorts with larger sample sizes are expected.
Identifiants
pubmed: 36205196
doi: 10.1111/1744-9987.13939
doi:
Substances chimiques
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-441Subventions
Organisme : National Center for Global Health and Medicine
ID : 19A-2014
Organisme : National Center for Global Health and Medicine
ID : 21A-2002
Informations de copyright
© 2022 International Society for Apheresis and Japanese Society for Apheresis.
Références
WHO. Global tuberculosis report 2021. 2021.
WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018.
Dobler CC, McDonald SP, Marks GB. Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One. 2011;6(12):e29563.
Ferguson TW, Tangri N, Macdonald K, Hiebert B, Rigatto C, Sood MM, et al. The diagnostic accuracy of tests for latent tuberculosis infection in hemodialysis patients: a systematic review and meta-analysis. Transplantation. 2015;99(5):1084-91.
Inoue T, Nakamura T, Katsuma A, Masumoto S, Minami E, Katagiri D, et al. The value of QuantiFERON TB-gold in the diagnosis of tuberculosis among dialysis patients. Nephrol Dial Transplant. 2009;24(7):2252-7.
Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3-20.
Shafeque A, Bigio J, Hogan CA, Pai M, Banaei N. Fourth-generation QuantiFERON-TB gold plus: what is the evidence? J Clin Microbiol. 2020;58(9):e01950-19.
Mamishi S, Pourakbari B, Marjani M, Mahmoudi S. Diagnosis of latent tuberculosis infection among immunodeficient individuals: review of concordance between interferon-gamma release assays and the tuberculin skin test. Br J Biomed Sci. 2014;71(3):115-24.
Hayakawa K, Kutsuna S, Kawamata T, Sugiki Y, Nonaka C, Tanaka K, et al. SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine. Glob Health Med. 2020;2(2):107-11.
Rogerson TE, Chen S, Kok J, Hayen A, Craig JC, Sud K, et al. Tests for latent tuberculosis in people with ESRD: a systematic review. Am J Kidney Dis. 2013;61(1):33-43.
Chiang LY, Baumann B, Romanowski K, Kumar D, Campbell JR, Djurdjev O, et al. Latent tuberculosis therapy outcomes in dialysis patients: a retrospective cohort. Am J Kidney Dis. 2021;77(5):696-703.
Tuberculosis in Japan: Annual Report 2021, [cited 2022 Sep 12]. https://jata.or.jp/english/dl/pdf/TB_in_Japan_2021.pdf.
Shu CC, Hsu CL, Lee CY, Wang JY, Wu VC, Yang FJ, et al. Comparison of the prevalence of latent tuberculosis infection among non-dialysis patients with severe chronic kidney disease, patients receiving dialysis, and the dialysis-unit staff: a cross-sectional study. PLoS One. 2015;10(4):e0124104.
Wang PH, Lin SY, Lee SS, Lin SW, Lee CY, Wei YF, et al. CD4 response of QuantiFERON-TB gold plus for positive consistency of latent tuberculosis infection in patients on dialysis. Sci Rep. 2020;10(1):21367.
Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, et al. First evaluation of QuantiFERON-TB gold plus performance in contact screening. Eur Respir J. 2016;48(5):1411-9.